- Home
- PDS vs EVMN Comparison
PDS vs EVMN Comparison
Compare PDS & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDS | EVMN |
|---|---|---|
| Founded | 1951 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 892.4M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | PDS | EVMN |
|---|---|---|
| Price | $93.93 | $23.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $122.33 | $43.29 |
| AVG Volume (30 Days) | 122.6K | ★ 234.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.09 | N/A |
| Revenue Next Year | $2.10 | N/A |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.20 | $13.89 |
| 52 Week High | $103.80 | $33.20 |
Technical Indicators
Market Signals| Indicator | PDS | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 50.75 |
| Support Level | $85.27 | $21.14 |
| Resistance Level | $103.80 | $25.50 |
| Average True Range (ATR) | 3.83 | 1.97 |
| MACD | -0.87 | -0.05 |
| Stochastic Oscillator | 25.34 | 63.38 |
Price Performance
Historical ComparisonAbout PDS Precision Drilling Corporation
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.